Trials / Unknown
UnknownNCT04638270
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Anti-CD19 FasT CAR-T Cell Therapy for Patients With B Cell NHL: a Multi-center, Uncontrolled Trial.
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Xinqiao Hospital of Chongqing · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. To make a further improvement, adapting the FasT CAR-T cells manufacture technology to shorten the manufacturing time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 targeted CAR-T cell therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-CD19 FasT CAR-T cells | Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion. |
Timeline
- Start date
- 2020-11-21
- Primary completion
- 2021-11-01
- Completion
- 2023-11-01
- First posted
- 2020-11-20
- Last updated
- 2020-11-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04638270. Inclusion in this directory is not an endorsement.